
Viemed Healthcare VMD
$ 7.26
0.41%
Quarterly report 2025-Q3
added 11-05-2025
Viemed Healthcare Deferred Revenue 2011-2026 | VMD
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Viemed Healthcare
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.21 M | 4.62 M | 3.75 M | 3.41 M | 3.32 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.21 M | 3.32 M | 4.26 M |
Quarterly Deferred Revenue Viemed Healthcare
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.81 M | 7.19 M | 6.8 M | 6.69 M | 6.82 M | 6.72 M | 6.09 M | 6.21 M | 6.22 M | 5.96 M | 4.7 M | 4.62 M | 4.64 M | - | 3.89 M | 3.75 M | 3.8 M | 3.74 M | 3.42 M | 3.41 M | 3.41 M | 3.41 M | 3.41 M | 3.32 M | 3.32 M | 3.32 M | 3.32 M | 2.59 M | 2.48 M | 2.27 M | 2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.81 M | 2 M | 4.51 M |
Deferred Revenue of other stocks in the Medical devices industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Abiomed
ABMD
|
24.3 M | - | - | $ 17.2 B | ||
|
Acutus Medical
AFIB
|
401 K | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
563 K | - | 3.58 % | $ 2.21 M | ||
|
Apollo Endosurgery
APEN
|
88 K | - | - | $ 475 M | ||
|
Cognyte Software Ltd.
CGNT
|
127 M | $ 9.57 | 0.1 % | $ 687 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
508 K | - | - | $ 1.77 B | ||
|
Alphatec Holdings
ATEC
|
10.5 M | $ 22.65 | -0.15 % | $ 3.24 B | ||
|
AxoGen
AXGN
|
14 K | $ 33.63 | 0.78 % | $ 1.49 B | ||
|
Apyx Medical Corporation
APYX
|
500 K | $ 3.5 | 1.16 % | $ 121 M | ||
|
EDAP TMS S.A.
EDAP
|
6.64 M | $ 3.66 | -3.56 % | $ 136 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
424 K | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
47.8 M | $ 323.76 | 1.47 % | $ 9.13 B | ||
|
BioSig Technologies
BSGM
|
16 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
306 M | $ 97.6 | -0.79 % | $ 144 B | ||
|
Conformis
CFMS
|
215 K | - | - | $ 16.4 M | ||
|
Bruker Corporation
BRKR
|
438 M | $ 54.12 | 3.12 % | $ 8.06 K | ||
|
InMode Ltd.
INMD
|
11.9 M | $ 14.47 | 1.47 % | $ 1.15 B | ||
|
CryoLife, Inc.
CRY
|
1.45 M | - | -4.14 % | $ 702 M | ||
|
IRIDEX Corporation
IRIX
|
2.4 M | $ 1.16 | -2.94 % | $ 18.7 M | ||
|
Cardiovascular Systems
CSII
|
2.11 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
10.4 M | - | -10.19 % | $ 1.99 M | ||
|
LENSAR
LNSR
|
1.68 M | $ 11.6 | -0.6 % | $ 134 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
33 | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
732 K | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
13.3 K | - | - | $ 462 M | ||
|
Dynatronics Corporation
DYNT
|
150 K | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
621 K | - | - | $ 10.2 M | ||
|
Intersect ENT, Inc.
XENT
|
137 K | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
335 K | - | -0.97 % | $ 54.4 M | ||
|
Align Technology
ALGN
|
1.33 B | $ 172.23 | 0.97 % | $ 12.9 B | ||
|
Accuray Incorporated
ARAY
|
82.3 M | $ 0.89 | -0.47 % | $ 91.5 M | ||
|
IRadimed Corporation
IRMD
|
2.26 M | $ 98.81 | -1.19 % | $ 1.25 B | ||
|
ClearPoint Neuro
CLPT
|
2.12 M | $ 15.06 | -1.63 % | $ 407 M | ||
|
FONAR Corporation
FONR
|
4.29 M | $ 18.56 | 0.02 % | $ 122 M | ||
|
Sintx Technologies
SINT
|
4.72 K | $ 3.78 | -1.32 % | $ 14.1 M | ||
|
Sensus Healthcare
SRTS
|
541 K | $ 4.82 | 8.8 % | $ 78.6 M | ||
|
Globus Medical
GMED
|
22.1 M | $ 94.0 | -0.66 % | $ 12.8 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
10.5 M | $ 13.69 | -1.23 % | $ 1.05 B |